A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children.
A Laura NijstadEvelien de Vos-KerkhofCatherine F Enters-WeijnenMarianne D van de WeteringWim J E TissingLidwien M HanffRogier LangeMatthijs M TibbenHilde RosingArief LalmohamedC Michel ZwaanAlwin D R HuitemaPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
Our extemporaneous oral suspension is an adequate alternative for the commercially (un)available oral suspension in young children. An adequate exposure to aprepitant in children was yielded and the bioavailability of the extemporaneous suspension was comparable to capsules.
Keyphrases